Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
XERS Xeris Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: XERS
Price (delayed)
$4.88
Market cap
$781.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.3
Enterprise value
$991.87M
Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
Highlights
XERS's EPS is up by 35% year-on-year and by 19% since the previous quarter
The net income has grown by 30% YoY and by 18% from the previous quarter
XERS's quick ratio is down by 36% year-on-year
XERS's equity is down by 19% since the previous quarter
Key stats
What are the main financial stats of XERS
Market
Valuations
Earnings
Shares outstanding
160.16M
Market cap
$781.56M
Enterprise value
$991.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.46
Revenue
$222.55M
Gross profit
$182.96M
Operating income
-$22.49M
Net income
-$45.08M
EBIT
-$16.89M
EBITDA
-$4.34M
Free cash flow
-$27.43M
Per share
Balance sheet
Liquidity
EPS
-$0.3
EPS diluted
-$0.3
Free cash flow per share
-$0.18
Book value per share
-$0.23
Revenue per share
$1.46
TBVPS
$1.29
Total assets
$315.45M
Total liabilities
$350.58M
Debt
$268.75M
Equity
-$35.13M
Working capital
$68.42M
Debt to equity
-7.65
Current ratio
1.72
Quick ratio
1.1
Net debt/EBITDA
-48.47
Margins
Efficiency
Dividend
EBITDA margin
-1.9%
Gross margin
82.2%
Net margin
-20.3%
Operating margin
-10.1%
Return on assets
-14%
Return on equity
N/A
Return on invested capital
-5.3%
Return on capital employed
-7.7%
Return on sales
-7.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XERS stock price
How has the Xeris Pharmaceuticals stock price performed over time
Intraday
1.88%
1 week
-2.59%
1 month
19.61%
1 year
141.58%
YTD
43.95%
QTD
-11.11%
Financial performance
How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$222.55M
Gross profit
$182.96M
Operating income
-$22.49M
Net income
-$45.08M
Gross margin
82.2%
Net margin
-20.3%
Xeris Pharmaceuticals's operating margin has soared by 61% YoY and by 39% from the previous quarter
The operating income has grown by 50% year-on-year and by 33% since the previous quarter
The net margin has grown by 46% YoY and by 25% from the previous quarter
The net income has grown by 30% YoY and by 18% from the previous quarter
Price vs fundamentals
How does XERS's price correlate with its fundamentals
Growth
What is Xeris Pharmaceuticals's growth rate over time
Valuation
What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.46
XERS's EPS is up by 35% year-on-year and by 19% since the previous quarter
XERS's equity is down by 19% since the previous quarter
XERS's price to sales (P/S) is 37% less than its 5-year quarterly average of 5.2 but 26% more than its last 4 quarters average of 2.6
The company's revenue rose by 30% YoY and by 10% QoQ
Efficiency
How efficient is Xeris Pharmaceuticals business performance
XERS's ROS has soared by 66% year-on-year and by 42% since the previous quarter
The return on invested capital has surged by 59% year-on-year and by 35% since the previous quarter
The return on assets rose by 29% year-on-year and by 16% since the previous quarter
Dividends
What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XERS.
Financial health
How did Xeris Pharmaceuticals financials performed over time
The total assets is 10% less than the total liabilities
XERS's quick ratio is down by 36% year-on-year
XERS's current ratio is down by 27% year-on-year but it is up by 3% since the previous quarter
The debt to equity has soared by 74% YoY and by 17% from the previous quarter
XERS's equity is down by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.